Mounjaro Dosage Chart: Complete Titration Schedule and Dose Guide
Complete Mounjaro (tirzepatide) dosage chart with the FDA-approved titration schedule, maintenance doses, missed-dose rules, and evidence from SURPASS and SURMOUNT trials.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on April 18, 2026
Our medical review process ensures clinical accuracy and patient safety.
Mounjaro (tirzepatide) is a once-weekly injectable treatment for type 2 diabetes that works as a dual GIP/GLP-1 receptor agonist. Like other incretin therapies, it requires a structured dose-escalation schedule to minimize gastrointestinal side effects and reach an effective maintenance dose. This guide breaks down the full FDA-approved titration schedule, dose-adjustment rules, missed-dose handling, and the clinical evidence behind each step.
Mounjaro Dosage Chart: FDA-Approved Titration Schedule
Every patient starts Mounjaro at the same initial dose, regardless of body weight, A1C, or prior medication history. Dose increases happen in 2.5 mg increments every 4 weeks until an effective and tolerated dose is reached.
| Week | Weekly Dose | Purpose |
|---|---|---|
| 1–4 | 2.5 mg | Starter dose — tolerance only, not effective for glycemic control |
| 5–8 | 5 mg | First maintenance dose — minimum effective level |
| 9–12 | 7.5 mg (optional) | Intermediate — used if 5 mg is tolerated but glycemic targets not met |
| 13–16 | 10 mg | Second maintenance dose — most common long-term dose |
| 17–20 | 12.5 mg (optional) | Intermediate — used before committing to 15 mg |
| 21+ | 15 mg | Maximum FDA-approved dose |
Evidence: "The recommended starting dosage of tirzepatide is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage is 15 mg subcutaneously once weekly." — U.S. Food and Drug Administration. Mounjaro Prescribing Information. 2023. FDA Label
The 2.5, 7.5, and 12.5 mg doses are not maintenance doses. They exist purely to smooth the escalation path to the next effective dose level. Clinicians should not stop at 2.5 mg long-term because it does not produce clinically meaningful A1C reduction.
Available Maintenance Doses: 5, 10, and 15 mg
Three doses are considered effective maintenance options. The choice depends on glycemic response, tolerability, and individual clinical goals.
5 mg — Minimum effective dose
The lowest effective dose. Appropriate for patients who reach glycemic targets quickly or cannot tolerate higher doses due to persistent GI side effects.
10 mg — Most common long-term dose
A balance point between efficacy and tolerability. In the SURPASS-2 trial, 10 mg produced a 2.24% A1C reduction from baseline — superior to semaglutide 1 mg.
15 mg — Maximum dose
Reserved for patients needing further glycemic control after 4+ weeks at 10 mg. Produces the largest absolute A1C and weight reductions in pivotal trials, but with slightly higher GI adverse-event rates.
Evidence: "Tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. The estimated mean changes from baseline were −2.01% with 5 mg of tirzepatide, −2.24% with 10 mg of tirzepatide, −2.30% with 15 mg of tirzepatide, and −1.86% with semaglutide." — Frías JP, et al. SURPASS-2. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2107519
Dose Adjustment: When to Slow Down
The 4-week interval between dose increases is a minimum, not a mandate. The FDA label explicitly permits holding at a lower dose longer if side effects are significant.
When to pause escalation
- Persistent moderate-to-severe nausea or vomiting
- Dehydration risk (especially in older adults or patients on diuretics)
- Early signs of pancreatitis (severe abdominal pain radiating to the back) — stop and evaluate
- Rapid heart rate, chest symptoms, or signs of volume depletion
When to reduce the dose
If a dose increase triggers intolerable symptoms, stepping back to the previous dose for an additional 4 weeks is acceptable before re-attempting escalation. The goal is to reach a dose that provides benefit without unacceptable side effects — not to reach 15 mg as quickly as possible.
GI side effects by dose
| Symptom | 5 mg | 10 mg | 15 mg |
|---|---|---|---|
| Nausea | 12–18% | 15–22% | 18–24% |
| Diarrhea | 12–14% | 14–17% | 16–19% |
| Vomiting | 5–6% | 8–10% | 9–12% |
| Constipation | 6–7% | 7–8% | 7–9% |
| Decreased appetite | 5–7% | 9–11% | 11–13% |
Rates pooled from the SURPASS program. Symptoms are most common during dose escalation and typically improve within 4–8 weeks on a stable dose.
Missed Dose Rules
Mounjaro has a long half-life (~5 days), so modest timing variation does not dramatically affect drug levels. The FDA label specifies two rules:
- Within 4 days (96 hours) of the missed dose — inject as soon as possible and resume the normal weekly schedule.
- More than 4 days past the missed dose — skip it and take the next scheduled dose. Do not double-dose.
The minimum interval between any two doses should be at least 3 days (72 hours). This also governs day-of-week changes: if you want to move from Mondays to Thursdays, the gap between the last Monday dose and the first Thursday dose must be ≥72 hours.
Storage, Injection Site, and Handling
Dose is only one part of proper use. Mounjaro requires specific handling to preserve potency.
- Refrigerate at 36–46°F (2–8°C) in the original carton, protected from light
- Once at room temperature (up to 86°F / 30°C), the pen is stable for up to 21 days
- Do not freeze — freezing destroys the drug; discard any frozen pen
- Inject subcutaneously in the abdomen, thigh, or upper arm — rotate sites weekly
- Each pen is single-use; discard into an approved sharps container after use
For deeper coverage of injection technique and storage, see our GLP-1 injection techniques guide and GLP-1 storage and handling guide.
Dosing in Special Populations
Kidney impairment
No dose adjustment is required for any degree of renal impairment, including dialysis. However, monitor closely for dehydration-related decline in kidney function, especially with severe nausea or vomiting.
Hepatic impairment
No dose adjustment is required. Tirzepatide is metabolized primarily by proteolysis, so liver function has minimal effect on drug clearance.
Older adults
No age-based dose adjustment. Greater sensitivity in some older patients cannot be ruled out — slow titration and dehydration monitoring are prudent.
Pregnancy and lactation
Not recommended during pregnancy. Discontinue at least 2 months before a planned pregnancy due to the long half-life. Data in lactation are limited.
Mounjaro vs Zepbound: Same Drug, Different Indications
Mounjaro and Zepbound contain the identical active ingredient (tirzepatide) and share the same titration schedule. The difference is the FDA-approved indication:
- Mounjaro — type 2 diabetes
- Zepbound — chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity
Both are manufactured by Eli Lilly, and both use the same 2.5 → 5 → 10 → 15 mg titration path. Insurance coverage typically tracks the labeled indication: most plans cover Mounjaro for diabetes and Zepbound for obesity when medical-necessity criteria are met.
For a head-to-head comparison with semaglutide, see our Tirzepatide vs Semaglutide pillar.
Key Takeaways
- Start at 2.5 mg weekly for 4 weeks, then escalate in 2.5 mg increments every 4 weeks
- 5, 10, and 15 mg are the effective maintenance doses — 2.5, 7.5, and 12.5 mg are escalation steps only
- Maximum approved dose is 15 mg weekly
- Pause or reduce escalation if side effects are intolerable — reaching 15 mg is not the goal; reaching an effective and tolerated dose is
- Missed-dose rule: inject within 96 hours, otherwise skip
- Day-of-week change: allowed as long as doses are separated by ≥72 hours
- Refrigerate pens; room-temperature stability is 21 days
References
U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. 2023. FDA Label
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. DOI: 10.1056/NEJMoa2107519
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6
Dahl D, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022;327(6):534-545. DOI: 10.1001/jama.2022.0078
Last updated: 2026-04-18 Medical review: Dr. James Chen, MD, PhD, FACE
Frequently Asked Questions
What is the starting dose of Mounjaro?
How often is the Mounjaro dose increased?
What is the maximum dose of Mounjaro?
What should I do if I miss a Mounjaro dose?
Can I change the day of the week I inject Mounjaro?
Why start at a low dose if higher doses work better?
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.